When pharmacists get involved in patient care, significant improvements are often seen. Diabetes management is one of the most notable examples.
Despite evidence that optimal glycemic control can help reduce disease progression and complications, most patients do not achieve recommended treatment goals.
FDA has approved two long-acting insulins by Novo Nordisk for the treatment of adults with diabetes mellitus.
Diabetes patients taking rosiglitazone or pioglitazone had a 28 percent lower incidence of Parkinson's disease (PD) than people taking other treatments for diabetes who had never taken the glitazone (GTZ) drugs, according to a new study.